Invited Review: Utilization of MG-ADL in myasthenia gravis clinical research and care-Article

Article

Pdf Summary

The Myasthenia Gravis Activities of Living (MG-ADL) scale is a reliable and valid measure that is used to assess symptoms and functional status in patients with myasthenia gravis (MG). It has been used as an outcome measure in clinical trials and observational studies to measure MG symptoms and response to treatment. While it is most often used as a secondary endpoint in clinical trials, its use as a primary endpoint has increased in recent years. The most common endpoint used with the MG-ADL is the change in score from baseline, but there has been an increase in the analysis of a responder threshold and minimal symptom expression (MSE). The MG-ADL has been found to be significantly correlated with other measures of MG, including the Myasthenia Gravis Composite (MGC), MG-II, MG-QOL15, and Manual Muscle Test (MMT). It is also significantly related to outcomes of fatigue and health-related quality of life (HRQoL). The MG-ADL has been validated in multiple languages and has been integrated into research as both a primary and secondary outcome measure. It is important for clinicians, researchers, and payers to understand how the MG-ADL should be used in clinical practice, clinical trials, and observational studies. The use of the MG-ADL as a primary endpoint in clinical trials and in responder threshold analyses to indicate treatment improvement has increased in recent years. MSE using the MG-ADL shows promise in helping to determine treatment success and may be the aspirational goal of MG treatment in the future.

Keywords

Myasthenia Gravis Activities of Living

MG-ADL scale

symptoms assessment

functional status

myasthenia gravis

clinical trials

observational studies

outcome measure

response to treatment

baseline score change